Pre-made Omburtamab benchmark antibody ( Whole mAb Radiolabelled, anti-CD276 therapeutic antibody, Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Omburtamab biosimilar, Whole mAb Radiolabelled, Anti-CD276 Antibody: Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Omburtamab (formerly burtomab) is a theranostic monoclonal antibody 8H9, conjugated to to 131 iodine, being developed by Y-mAbs Therapeutics, under a license from Memorial Sloan-Kettering Cancer Center, for the diagnosis and treatment of cancer.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-399-1mg	1mg	Inquiry
GMP-Bios-ab-399-10mg	10mg	Inquiry
GMP-Bios-ab-399-100mg	100mg	Inquiry
GMP-Bios-ab-399-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Omburtamab biosimilar, Whole mAb Radiolabelled, Anti-CD276 Antibody: Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2 therapeutic antibody
INN Name	Omburtamab
Target	CD276
Format	Whole mAb Radiolabelled
Derivation	Mouse
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II/III
Est. Status	Active
100% SI Structure	5cma:BA
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2018
Year Recommended	2019
Companies	Memorial Sloan-Kettering Cancer Center;Y-mAbs Therapeutics
Conditions Approved	na
Conditions Active	Neuroblastoma;Meningeal carcinomatosis;Soft tissue sarcoma;Peritoneal cancer
Conditions Discontinued	Solid tumours
Development Tech	na